Divis Laboratories Ltd vs Hikal Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Divis Laboratories Ltd is ₹ 6505 as of 30 Apr 15:30 . The P/E Ratio of Divis Laboratories Ltd changed from 48.6 on March 2021 to 69.8 on March 2025 . This represents a CAGR of 7.51% over 5 yearsThe P/E Ratio of Hikal Ltd changed from 13.3 on March 2021 to 54.4 on March 2025 . This represents a CAGR of 32.54% over 5 years The Market Cap of Divis Laboratories Ltd changed from ₹ 96366 crore on March 2021 to ₹ 153257 crore on March 2025 . This represents a CAGR of 9.72% over 5 yearsThe Market Cap of Hikal Ltd changed from ₹ 1769 crore on March 2021 to ₹ 4933 crore on March 2025 . This represents a CAGR of 22.76% over 5 years The revenue of Divis Laboratories Ltd for the Dec '25 is ₹ 2692 crore as compare to the Sep '25 revenue of ₹ 2860 crore. This represent the decline of -5.87% The revenue of Hikal Ltd for the Dec '25 is ₹ 497.1 crore as compare to the Sep '25 revenue of ₹ 320.4 crore. This represent the growth of 55.15% The ebitda of Divis Laboratories Ltd for the Dec '25 is ₹ 904 crore as compare to the Sep '25 ebitda of ₹ 1033 crore. This represent the decline of -12.49% The ebitda of Hikal Ltd for the Dec '25 is ₹ 47.5 crore as compare to the Sep '25 ebitda of ₹ 9.1 crore. This represent the growth of 421.98% The net profit of Divis Laboratories Ltd changed from ₹ 430 crore to ₹ 583 crore over 7 quarters. This represents a CAGR of 19.00% The net profit of Hikal Ltd changed from ₹ 5.1 crore to ₹ -5.9 crore over 7 quarters. This represents a CAGR of NaN% The Dividend Payout of Divis Laboratories Ltd changed from 27.16 % on March 2021 to 35.99 % on March 2025 . This represents a CAGR of 5.79% over 5 yearsThe Dividend Payout of Hikal Ltd changed from 18.52 % on March 2021 to 10.87 % on March 2025 . This represents a CAGR of -10.11% over 5 years .

About Divis Laboratories Ltd

Divi's Laboratories Limited is one of the leading pharmaceutical companies in the world, manufacturing Active Pharmaceutical Ingredients (APIs), Intermediates and Nutraceuticals.
The Company is one of the world's largest API companies, with two manufacturing units and a market presence across 100 countries.
It is engaged in the manufacture of Active Pharmaceutical ingredients (API's), Intermediates and Nutraceutical ingredients with predominance in exports.
In addition to generic business, the Company, through its custom synthesis business, supports innovator pharma companies for their patented products business right from gram scale requirements for clinical trials to launch as well as late life cycle management.
It is among the largest pharmaceutical companies in India with a portfolio of approx.

About Hikal Ltd

Hikal Limited, incorporated on July 8, 1988, has emerged as one of the preferred partners for global companies in segments such as pharmaceuticals, crop protection, animal health, biocides, and specialty chemicals.
The Company is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharma ingredients and contract research activities. The Company has 5 manufacturing facilities across three states in India.
It supply products to customers across the globe in the US, Japan, Europe, Canada, South East Asia, LATAM, India and RoW. Apart from this, it specialize in manufacturing APIs and intermediates in pharmaceutical division.
Within pharmaceutical division, it offer human health and animal health products. Hikal commenced its first project in 1991 at its first greenfield site at M.

FAQs for the comparison of Divis Laboratories Ltd and Hikal Ltd

Which company has a larger market capitalization, Divis Laboratories Ltd or Hikal Ltd?

Market cap of Divis Laboratories Ltd is 172,696 Cr while Market cap of Hikal Ltd is 2,340 Cr

What are the key factors driving the stock performance of Divis Laboratories Ltd and Hikal Ltd?

The stock performance of Divis Laboratories Ltd and Hikal Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Divis Laboratories Ltd and Hikal Ltd?

As of May 3, 2026, the Divis Laboratories Ltd stock price is INR ₹6505.35. On the other hand, Hikal Ltd stock price is INR ₹189.85.

How do dividend payouts of Divis Laboratories Ltd and Hikal Ltd compare?

To compare the dividend payouts of Divis Laboratories Ltd and Hikal Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.